HepaTx is focused on applying regenerative medicine to liver disease. Our lead product, Hx-001, addresses the large and completely unmet need in late stage liver disease. This single product is promising in multiple indications, including MetALD, alcohol-associated liver disease, and MASH giving us a pipeline in this single product. Hx-001 is being developed in collaboration with the Mayo Clinic and is expected to complete Phase I clinical trials in 18 months. A Stanford spin-off company, Hepatx has exclusive world-wide rights to critical enabling technology for Hx-001. HepaTx has in-vitro and in-vivo data demonstrating that our hepatocyte-like cells reduce liver damage, reduce inflammation, and promote regeneration in animal models. With a strong and experienced team, strong IP, a deep pipeline, and world-class advisors, there’s an exciting future ahead for HepaTx. We hope you will join us on the journey.